On this page you will find information for pharmacists involved in the RECOVERY Trial, including FAQs and HRA Pharmacy Assurance.
July 2023: RECOVERY trial sotrovimab has received a further expiry date extension, to 36 months. This will require relabelling existing stock. Please see sotrovimab 36 month expiry documents below.
June 2023: Following the closing of the molnupiravir and Paxlovid arms, sites should return any unused study drug to the site pharmacy for general use, following their local guidelines.
RECOVERY Trial pharmacy briefing document and FAQs (This version was updated on 14 December 2023 to align with protocol v27.0)
Sotrovimab expiry date extension